A survey sought to clarify teens' perceptions of recreational use of prescription drugs.
An abuse liability assessment was conducted to determine the abuse potential and pharmacokinetics of extended-release vs immediate-release oxycodone.
Ketoprofen was found to be effective in relieving moderate to severe pain in patients with rheumatoid arthritis.
NKTR-181 was found to be safe and effective in patients with low back pain.
Sleep-onset insomnia, pain intensity, and daytime dysfunction contribute to risk of suicide in patients diagnosed with chronic pain.
Multiple new drugs for pain management have been recently introduced or approved, and additional agents are currently under investigation.
A growing body of research is showing the importance of bolstering resilience in chronic pain management.
Treatment of neuroinflammation as the underlying cause of chronic, severe pain involves several components: standard pain relief, neuroinflammation control, spinal flow exercises, and neuroregeneration.
Dr Witzeman focused on integrative modalities for the treatment of female chronic pelvic pain.
At PAINWeek 2017, the president of the National Association of Drug Diversion Investigators discussed ways to balance pain management needs and overdose prevention measures.
At PAINWeek 2017, Dr Joshi gave on overview of stem cell therapies used in regenerative medicine to treat a number of pain conditions.
In patients with concomitant fibromyalgia and PTSD, opioid therapy was shown to improve quality of life and help patients return to a greater sense of "normalcy."
In patients with opioid-induced constipation, naldemedine was shown to improve patient assessment of symptoms and quality of life.
Participation in a pilot functional medicine clinic decreased perceived stress and joint and muscle symptoms in veterans with chronic pain.
Opioid treatment of acute postoperative pain was shown to cause high rates of postoperative nausea and vomiting, particularly in women and younger patients.
Administration of abuse-deterrent formulations of immediate-release oxycodone and extended-release morphine leads to slower and lower absorption rates in nondependent recreational drug users compared with standard oxycodone and morphine formulations.
Dr Gould covered the risks of co-prescribing benzodiazepines and opioids, particularly for elderly patients, and proposed therapeutic alternatives at PAINWeek 2017.
Dr Zacharoff provided advice for clinicians dealing with fluid guidelines and constraints regarding opioid prescribing.
Effective coaching strategies for the management of complicated pain were presented.
Dr McMaster gave an overview of differential diagnostic studies for pain pathologies, their utility in the clinic, and their limitations.
Dr Tick presented evidence linking nutrition, microbial diversity, and pain.
Dr Cuevas-Trisan covered the evaluation and management of diabetic peripheral neuropathic pain during his presentation at PAINWeek 2017.
Jennifer Bolen, JD, provides PAINWeek 2017 attendees with information on risk reduction and response to medication overdose events.
Dr Clark sought to outline a comprehensive approach to the assessment and follow-up of patients with chronic pain.
Virtual reality is on the verge of revolutionizing pain management, including on the chronic pain front, and may offer a new way to combat the opioid crisis.
Psychological factors are an important yet often overlooked target for improving chronic pain management.
Preemptive analgesia seeks to prevent central sensitization and ensuing chronic pain, a concept that has shown promising results in preliminary studies.
Behavioral techniques such as motivational interviewing may facilitate the tapering process.
At PAINWeek, Dr Hah focused on the risks of long-term opioid use for chronic noncancer pain and reviewed guidelines regarding the tapering of these medications.
Clinical Pain Advisor Articles
- Opioid Use Disorders: Advances in Pharmacotherapy Provide Long-term Results
- Abuse-Deterrent Opioid Formulations: Barriers to Broader Use
- Women Frequently Prescribed High Doses of Opioids After Vaginal Delivery
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Medical Cannabis Legalization Associated With Reduced Schedule III Opioid Prescriptions
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- Prioritizing Rest in Hospital Settings: Poor Sleep Increases Costs, Complications, and Mortality
- Pain Catastrophizing Decreases in Rheumatoid Arthritis After DMARD Initiation
- Addressing Commercial Incentives in the Medical Device Industry
- Cancer Patients Treated With Step III Opioids Often Have Sleep Disturbances
- Individual, Group Low Literacy Self-Management Program for Chronic Pain May Be Effective